Head-line is - Ellex iTrackTM global sales were US$6.1 million for the nine month period, up 40% on prior comparative period.
If you break it down further, sales in both the US and Asia (mainly China) were above 50% with strong momentum. Bodes well for the future.
Re the US, this was despite sales from the Soutwest falling which they are seeking to rectify. East coast sales strong off a low base. Also suggesting increasing traction among surgeons.
Note expecting recent investment in sales/marketing head-count to drive continued momentum in Q4.
ROW is ok - but given this is a US first & then Asia story for iTrack I am pleased with the momentum & provides early validation for the investment in sales / mkt opex (for which ELX was punished by the market in the last reporting season).
Ann: Glaucoma Business FY18Q3 Sales Update, page-2
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $62.92M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 27.5¢ | $71.02K | 249.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 164060 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 53168 | 4 |
View Market Depth
| Last trade - 11.46am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.0¢ |
Change
0.000 ( 1.82 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 28.5¢ | 28.0¢ | 108009 | ||
| Last updated 12.15pm 22/05/2024 ? | |||||
| EYE (ASX) Chart |